2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.Peer-Reviewed Original ResearchBreast cancerYounger patientsHER2-negative breast cancerNode-positive breast cancerNode-negative diseaseSame clinical featuresHigh mutation burdenLower mRNA expressionAdjuvant chemotherapyMicroarray cohortTAILORx trialOvarian suppressionOlder patientsPatient ageClinical featuresProliferation-related gene expressionScore 0Mutation burdenCopy number gainsOlder womenGATA3 mutationsAge groupsGene signatureMRNA expressionChemotherapy
2001
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
Buchholz T, Hill B, Tucker S, Frye D, Kuerer H, Buzdar A, McNeese M, Singletary S, Ueno N, Pusztai L, Valero V, Hortobagyi G. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. The Cancer Journal 2001, 7: 413-20. PMID: 11693900.Peer-Reviewed Original ResearchConceptsEstrogen receptor-negative diseaseReceptor-negative diseaseLocal-regional recurrenceLocal-regional recurrence ratePositive lymph nodesNeoadjuvant chemotherapyLymph nodesOverall survivalProgressive diseaseRecurrence rateLymph node-negative diseaseSignificant poorer overall survivalEstrogen receptor-positive diseaseBreast cancer refractoryInvolved lymph nodesNegative lymph nodesReceptor-positive diseaseNode-negative diseasePostoperative radiation therapyInitial clinical stageCox regression analysisBreast cancer patientsPoor overall survivalAdjuvant chemotherapyCancer refractory